Skin-texture drug triggers: Can 2025’s tactile medications enhance psychiatric treatment adherence?

Abstract

Get full access to this article

View all access options for this article.

References

Quality ID #383 (NQF 1879): adherence to antipsychotic medications for individuals with schizophrenia, 2020.

Prausnitz

Langer

Transdermal drug delivery. Nat Biotechnol 2008; 26(11): 1261–1268.

Ouyang

Feng

Kuang

, et al. Self-powered, on-demand transdermal drug delivery system driven by triboelectric nanogenerator. Nano Energy 2019; 62: 610–619.

Adherence to treatment in dermatology: literature review - Lo - 2024 - JEADV Clinical Practice - Wiley Online Library. https://onlinelibrary.wiley.com/doi/full/10.1002/jvc2.379?msockid=367433cbfccb693b0db1262dfd996859 (accessed 18 May 2025).

Chen

Xing

Lei

, et al. ROS-driven supramolecular nanoparticles exhibiting efficient drug delivery for chemo/chemodynamic combination therapy for Cancer treatment. J Contr Release 2024; 368: 637–649.

Shiva Shanker Reddy

Chaturvedi

. Psychosocial issues in dermatology. EMJ Dermatol 2017; 83–89.

Kaye

Islam

Castine

, et al. Exploring the relationship between psychiatric illness and dermatological disorders: a narrative review. Cureus. 2025; 17(2): e78731.

Aziz

AFA

Beh

Farahiyah

, et al. A review on the mechanisms, applications, and clinical trials of advanced technologies in the transdermal drug delivery system. https://www.eurekaselect.com (accessed 2 July2025)

Lilienfeld

Lynn

Lohr

. Science and pseudoscience in clinical psychology.